Der Nervenarzt

, Volume 81, Issue 8, pp 956–962 | Cite as

Verlauf und Behandlung der Myasthenia gravis in der Schwangerschaft

Übersichten

Zusammenfassung

Familienplanung und Kinderwunsch sind häufig diskutierte Fragen in der Myastheniesprechstunde, da die Erstmanifestation häufig in die Lebensphase der Familienplanung fällt. Schwangerschaft, Geburt und Stillen bei Myastheniepatientinnen sind zwar mit einigen Besonderheiten verbunden, stellen in der Regel aber kein nennenswert erhöhtes Risiko im Vergleich zu normaler Schwangerschaft, Geburt und Wochenbett dar. Immer wiederkehrende Fragen betreffen sowohl den Verlauf der Schwangerschaft als auch den Einfluss der Myasthenie und insbesondere der medikamentösen Therapie auf die Schwangerschaft und das ungeborene Kind bzw. das Neugeborene. Einen besonderen Stellenwert nimmt hierbei die Frage der Entbindung ein, da es nach wie vor weit verbreitet ist, Myastheniepatientinnen primär per sectio zu entbinden.

Diese Übersicht soll als Grundlage für die individuelle Beratung und Betreuung von Myastheniepatientinnen dienen, die mit Kinderwunsch oder bereits eingetretener Schwangerschaft in die neurologische Sprechstunde kommen.

Schlüsselwörter

Myasthenia gravis Schwangerschaft Stillzeit Geburt Therapie 

Course and treatment of myasthenia gravis during pregnancy

Summary

Pregnancy and family planning issues are frequent concerns in the medical care of patients with myasthenia gravis since disease onset often coincides with the life period which is decisive in this respect. Although pregnancy, delivery and breastfeeding represent special circumstances in these patients, they are not associated with higher risks of complications compared to normal pregnancy, delivery and postpartum period. Frequently asked questions regard the course of pregnancy as well as the impact of the disease and particularly medical treatment on pregnancy and the foetus or neonate. Great significance is attached to the mode of delivery since it is still widely accepted that patients with myasthenia gravis have to deliver per elective caesarean section. This paper gives an overview and provides a basis for the medical care and individual counselling of patients with myasthenia gravis who want to start a family or are already pregnant.

Keywords

Myasthenia gravis Pregnancy Nursing Birth Therapy 

Literatur

  1. 1.
    Armenti V, Radomski JS, Moritz MJ et al (2003) Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 131–141Google Scholar
  2. 2.
    Barnes PR, Kanabar DJ, Brueton L et al (1995) Recurrent congenital arthrogryposis leading to a diagnosis of myasthenia gravis in an initially asymptomatic mother. Neuromuscul Disord 5:59–65CrossRefPubMedGoogle Scholar
  3. 3.
    Batocchi AP, Majolini L, Evoli A et al (1999) Course and treatment of myasthenia gravis during pregnancy. Neurology 52:447–452PubMedGoogle Scholar
  4. 4.
    Buckley LM, Bullaboy CA, Leichtman L et al (1997) Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 40:971–973CrossRefPubMedGoogle Scholar
  5. 5.
    Cohen BA, London RS, Goldstein PJ (1976) Myasthenia gravis and preeclampsia. Obstet Gynecol 48:35S–37SPubMedGoogle Scholar
  6. 6.
    Davison JM, Dellagrammatikas H, Parkin JM (1985) Maternal azathioprine therapy and depressed haemopoiesis in the babies of renal allograft patients. Br J Obstet Gynaecol 92:233–239PubMedGoogle Scholar
  7. 7.
    Djelmis J, Sostarko M, Mayer D et al (2002) Myasthenia gravis in pregnancy: report on 69 cases. Eur J Obstet Gynecol Reprod Biol 104:21–25CrossRefPubMedGoogle Scholar
  8. 8.
    Enns GM, Roeder E, Chan RT et al (1999) Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 86:237–241CrossRefPubMedGoogle Scholar
  9. 9.
    Ferrero S, Pretta S, Nicoletti A et al (2005) Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol 121:129–138CrossRefPubMedGoogle Scholar
  10. 10.
    Fraser D, Turner JW (1953) Myasthenia and pregnancy. Lancet 265:417–419CrossRefPubMedGoogle Scholar
  11. 11.
    Gaudier FL, Santiago-Delpin E, Rivera J et al (1988) Pregnancy after renal transplantation. Surg Gynecol Obstet 167:533–543PubMedGoogle Scholar
  12. 12.
    Gurjar M, Jagia M (2005) Successful management of pregnancy-aggravated myasthenic crisis after complete remission of the disease. Aust N Z J Obstet Gynaecol 45:331–332CrossRefPubMedGoogle Scholar
  13. 13.
    Hall JG, Reed SD (1982) Teratogens associated with congenital contractures in humans and in animals. Teratology 25:173–191CrossRefPubMedGoogle Scholar
  14. 14.
    Hoff JM, Daltveit AK, Gilhus NE (2003) Myasthenia gravis: consequences for pregnancy, delivery, and the newborn. Neurology 61:1362–1366PubMedGoogle Scholar
  15. 15.
    Hoff JM, Daltveit AK, Gilhus NE (2007) Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 14:38–43CrossRefPubMedGoogle Scholar
  16. 16.
    Jain AB, Venkataramanan R, Fung JJ et al (1997) Pregnancy after liver transplantation under tacrolimus. Transplantation 64:559–565CrossRefPubMedGoogle Scholar
  17. 17.
    Jain AB, Reyes J, Marcos A et al (2003) Pregnancy after liver transplantation with tacrolimus immunosuppression: a single center’s experience update at 13 years. Transplantation 76:827–832CrossRefPubMedGoogle Scholar
  18. 18.
    Janssen NM, Genta MS (2000) The effects of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med 160:610–619CrossRefPubMedGoogle Scholar
  19. 19.
    Kaynar L, Altuntas F, Aydogdu I et al (2008) Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Transfus Apher Sci 38:109–115CrossRefPubMedGoogle Scholar
  20. 20.
    Kerr JR (2005) Neonatal effects of breast cancer chemotherapy administered during pregnancy. Pharmacotherapy 25:438–441CrossRefPubMedGoogle Scholar
  21. 21.
    Klink DT, Elburg RM van, Schreurs MW et al (2008) Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008:271363Google Scholar
  22. 22.
    Lamarque V, Leleu MF, Monka C et al (1997) Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun. Transplant Proc 29:2480CrossRefPubMedGoogle Scholar
  23. 23.
    Le Ray C, Coulomb A, Elefant E et al (2004) Mycophenolate mofetil in pregnancy after renal transplantation: a case of major fetal malformations. Obstet Gynecol 103:1091–1094Google Scholar
  24. 24.
    Lefvert AK, Osterman PO (1983) Newborn infants to myasthenic mothers: a clinical study and an investigation of acetylcholine receptor antibodies in 17 children. Neurology 33:133–138PubMedGoogle Scholar
  25. 25.
    Licht C, Model P, Kribs A et al (2002) Transiente neonatale Myasthenia gravis. Nervenarzt 73:774–778CrossRefPubMedGoogle Scholar
  26. 26.
    Moskovitz DN, BodianC, Chapman ML et al (2004) The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 99:656–661CrossRefPubMedGoogle Scholar
  27. 27.
    Notarianni LJ, Belk D, Aird SA et al (1995) An in vitro technique for the rapid determination of drug entry into breast milk. Br J Clin Pharmacol 40:333–337PubMedGoogle Scholar
  28. 28.
    Paladini D, Vassallo M, D’Armiento MR et al (2004) Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol 70:99–100CrossRefPubMedGoogle Scholar
  29. 29.
    Papazian O (1992) Transient neonatal myasthenia gravis. J Child Neurol 7:135–141CrossRefPubMedGoogle Scholar
  30. 30.
    Peres RM, Sanseverino MT, Guimaraes JL et al (2001) Assessment of fetal risk associated with exposure to cancer chemotherapy during pregnancy: a multicenter study. Braz J Med Biol Res 34:1551–1559CrossRefPubMedGoogle Scholar
  31. 31.
    Plauche WC (1991) Myasthenia gravis in mothers and their newborns. Clin Obstet Gynecol 34:82–99CrossRefPubMedGoogle Scholar
  32. 32.
    Polizzi A, Huson SM, Vincent A (2000) Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology 62:332–341CrossRefPubMedGoogle Scholar
  33. 33.
    Powell HR, Ekert H (1971) Methotrexate-induced congenital malformations. Med J Aust 2:1076–1077PubMedGoogle Scholar
  34. 34.
    Rodriguez-Pinilla E, Martinez-Frias ML (1998) Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology 58:2–5CrossRefPubMedGoogle Scholar
  35. 35.
    Ross L (1995) Congenital anomalies in two infants born after gestational gamma-globulin prophylaxis. Acta Paediatr. 84:1436–1437Google Scholar
  36. 36.
    Schaefer C, Spielmann H, Vetter K (2006) Immunmodulatoren und Therapie rheumatischer Erkrankungen In: Schaefer C, Spielmann H, Vetter K (Hrsg) Arzneiverordnung in Schwangerschaft und Stillzeit. Urban und Fischer, München & Jena S 313–314Google Scholar
  37. 37.
    Schaefer C, Spielmann H, Vetter K (2006) Immunmodulatoren und Therapie rheumatischer Erkrankungen In: Schaefer C, Spielmann H, Vetter K (Hrsg) Arzneiverordnung in Schwangerschaft und Stillzeit. Urban und Fischer, München Jena, S 679Google Scholar
  38. 38.
    Schmidt PL, Sims ME, Strassner HT et al (1984) Effect of antepartum glucocorticoid administration upon neonatal respiratory distress syndrome and perinatal infection. Am J Obstet Gynecol 148:178–186PubMedGoogle Scholar
  39. 39.
    Schroder A, Ellrichmann G, Chehab G et al (2009) Einsatz von Rituximab in der Behandlung neuroimmunologischer Erkrankungen. Nervenarzt 80:155–60 162CrossRefPubMedGoogle Scholar
  40. 40.
    Scott JS (1977) Immunological diseases in pregnancy. Prog Allergy 23:321–366PubMedGoogle Scholar
  41. 41.
    Taylor P (1990) Anticholinesterase agents. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) The pharmacological basis of therapeutics. 8th ed. Pergamon, New York, S 131–149Google Scholar
  42. 42.
    Vaux KK, Kahole NC, Jones KL (2003) Cyclophosphamide, methotrexate, and cytarabine embropathy: is apoptosis the common pathway? Birth Defects Res A Clin Mol Teratol 67:403–408CrossRefPubMedGoogle Scholar
  43. 43.
    Vincent A, Newland C, Brueton L et al (1995) Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen. Lancet 346:24–25CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Klinik für NeurologieCharité-Universitätsmedizin BerlinBerlinDeutschland
  2. 2.Klinik für Neurologie, Myasthenie-Ambulanz, NeuroCure Clinical Research Center, Centrum für Schlaganfallforschung BerlinCharité-Universitätsmedizin BerlinBerlinDeutschland
  3. 3.Klinik für Geburtsmedizin, Charité Centrum für Frauen-, Kinder - und JugendmedizinCharité-Universitätsmedizin BerlinBerlinDeutschland

Personalised recommendations